NHLBI SBIR Phase IIB Bridge & Small Market Awards

Accepting applications beginning June 27, 2018

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional).

The Bridge Award supports Phase II SBIR or STTR awardees to advance NHLBI mission-related products to regulatory approval and eventual commercialization. The program promotespartnerships between SBIR/STTR Phase II awardees and third-party investors and/or strategic partners.

Read the full announcement: RFA-HL-19-017

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional).

The Small Market Award supports Phase II SBIR or STTR awardees that are developing NHLBI mission-related products that address a rare disease or young pediatric populations. The goal of this FOA is for these products to be further validated so that development can continue with private funding after NHLBI support ends.

Read the full announcement: RFA-HL-19-018
Due Dates:

Application: July 27, 2018; by 5:00 PM

Letter of Intent (optional but encouraged): June 27, 2018

Applicants are strongly encouraged to contact the program representative(s) listed in the announcement prior to submitting a proposal.

More information is available in the full Funding Opportunity Announcements RFA-HL-19-017RFA-HL-19-018 and by contacting

Gary Robinson, PhD 
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7978
Email: gary.robinson@nih.gov